<p>GatePass Capital LLC 在最近向證券交易委員會提交的 13F 文件中披露，在第四季度購買了 The Oncology Institute, Inc. (NASDAQ:TOI - 免費報告) 的新頭寸。該公司購買了 360,000 股該公司的股票，價值約為 1,282,000 美元。截至其最近的 SEC 文件，GatePass Capital LLC 持有 Oncology Institute 0.37% 的股份。</p>
<p>獲取 <strong>Oncology Institute</strong> 的提醒：</p>
<p>其他幾家對沖基金也調整了對 TOI 的持股。高盛集團在第一季度購買了價值 131,000 美元的 Oncology Institute 新頭寸。Geode Capital Management LLC 在第二季度將其在 Oncology Institute 的持股增加了 231.7%。Geode Capital Management LLC 目前持有 1,279,443 股該公司的股票，價值 2,623,000 美元，此前在此期間又購買了 893,696 股。Cetera Investment Advisers 在第二季度將其在 Oncology Institute 的持股增加了 35.0%。Cetera Investment Advisers 目前持有 17,545 股該公司的股票，價值 36,000 美元，此前在此期間又購買了 4,545 股。摩根大通在第二季度將其在 Oncology Institute 的持股增加了 51,631.5%。摩根大通目前持有 27,935 股該公司的股票，價值 57,000 美元，此前在此期間又購買了 27,881 股。最後，紐約州共同退休基金在第二季度購買了價值 92,000 美元的 Oncology Institute 新頭寸。目前，36.86% 的股票由機構投資者和對沖基金持有。</p>
<h2>分析師評級調整</h2>
<p>最近，一些研究分析師對 TOI 股票發佈了報告。Weiss Ratings 在 4 月 20 日的報告中重申了對 Oncology Institute 股票的 &#34;賣出 (d-)&#34; 評級。B. Riley Financial 在 3 月 13 日的報告中將 Oncology Institute 的目標價格從 6.00 美元上調至 8.00 美元，並給予該公司 &#34;買入&#34; 評級。Needham &amp; Company LLC 在 3 月 9 日的報告中重申了 &#34;買入&#34; 評級，並對 Oncology Institute 股票設定了 5.00 美元的目標價格。最後，BTIG Research 在 3 月 9 日的報告中重申了 &#34;買入&#34; 評級，並對 Oncology Institute 股票設定了 7.00 美元的目標價格。四位股票研究分析師對該股票給予了買入評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票目前的共識評級為 &#34;適度買入&#34;，共識目標價格為 7.00 美元。</p>
<p><strong>閲讀我們關於 TOI 的最新研究報告</strong></p>
<h2>Oncology Institute 的內部交易</h2>
<p>在其他消息中，董事 Mohit Kaushal 於 4 月 16 日出售了 38,433 股 Oncology Institute 股票。該股票的平均售價為 3.50 美元，總交易額為 134,515.50 美元。出售後，該董事在公司中持有 172,583 股，價值約為 604,040.50 美元。此次交易使其持股減少了 18.21%。該交易已在向證券交易委員會提交的文件中披露，文件可通過此鏈接訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。此外，主要股東 Jorey Chernett 於 5 月 20 日購買了 33,500 股該公司的股票。該股票的平均購買價格為每股 4.07 美元，總交易額為 136,345.00 美元。交易後，內部人士直接持有 10,567,858 股該公司的股票，價值約為 43,011,182.06 美元。這代表其持股增加了 0.32%。該購買的披露信息可在 SEC 文件中找到。內部人士在上個季度購買了價值 2,038,896 美元的 637,485 股公司股票。內部人士持有該公司 8.50% 的股份。</p>
<h2>Oncology Institute 股票表現</h2>
<p>TOI 週二開盤價為 4.59 美元。該公司的 50 天簡單移動平均線為 3.54 美元，200 天簡單移動平均線為 3.33 美元。The Oncology Institute, Inc. 的一年低點為 2.02 美元，一年高點為 4.88 美元。該股票的市值為 4.5368 億美元，市盈率為 -12.41，貝塔值為 0.33。</p>
<p>Oncology Institute (NASDAQ:TOI - 獲取免費報告) 最近一次發佈財報是在 5 月 7 日。該公司報告季度每股收益為 ($0.02)，超出分析師共識預期的 ($0.07) 0.05 美元。該公司季度收入為 1.4744 億美元，而分析師預期為 1.4210 億美元。平均而言，股票研究分析師預測 The Oncology Institute, Inc. 本財年將發佈 -0.2 的每股收益。</p>
<h2>Oncology Institute 簡介</h2>
<p>(免費報告)</p>
<p>The Oncology Institute, Inc. 是一家腫瘤學公司，在美國提供各種醫療腫瘤學服務。該公司通過三個部門運營：藥房、患者服務和臨牀試驗及其他。它提供醫生服務、內部輸液和藥房、臨牀試驗、放射治療、門診血液產品輸血和患者支持服務，以及教育研討會、支持小組和諮詢服務。該公司還提供管理臨牀試驗、姑息治療項目、幹細胞移植服務以及與非社區基礎的學術和三級護理設置相關的其他護理交付模式；併為一系列製藥和醫療設備公司進行臨牀試驗。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票超過 Oncology Institute</li>
<li>SpaceX 引起關注，但這四隻股票可能帶來回報</li>
<li>微軟股票折扣可能結束，因 AI 催化劑增加</li>
<li>服裝收益贏家和輸家：拉爾夫·勞倫起飛</li>
<li>為什麼沃爾瑪、塔吉特和 TJX 在財報後反應如此不同</li>
</ul>
<p><strong>想看看其他對沖基金持有 TOI 的情況嗎？</strong> 訪問 HoldingsChannel.com 獲取 The Oncology Institute, Inc. (NASDAQ:TOI - 免費報告) 的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE9J?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE9J"/></p>
<p><em>此即時新聞提醒是由敍事科學技術和來自 MarketBeat 的金融數據生成的，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Oncology Institute 嗎？</h2>
<p>在考慮 Oncology Institute 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Oncology Institute 並不在名單上。</p>
<p>雖然 Oncology Institute 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

醫藥突破 ETF - ALPS

2 倍做多納斯達克生物技術 ETF - ProShares

<p>GatePass Capital LLC 已投資 128 萬美元於 The Oncology Institute, Inc.，通過收購 360,000 股。其他對沖基金也調整了在 TOI 的持股。分析師對該股票的評級意見不一，普遍評級為 “適度買入”，目標價為 7.00 美元。該股票開盤價為 4.59 美元，市值為 4.5368 億美元。The Oncology Institute 報告的收益超出預期，上一季度的收入為 1.4744 億美元</p>

<p>GatePass Capital LLC purchased a new position in shares of The Oncology Institute, Inc. (NASDAQ:TOI - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The firm purchased 360,000 shares of the company's stock, valued at approximately $1,282,000. GatePass Capital LLC owned 0.37% of Oncology Institute as of its most recent SEC filing.</p>
<div class="lb-trans"><p>GatePass Capital LLC 在最近向證券交易委員會提交的 13F 文件中披露，在第四季度購買了 The Oncology Institute, Inc. (NASDAQ:TOI - 免費報告) 的新頭寸。該公司購買了 360,000 股該公司的股票，價值約為 1,282,000 美元。截至其最近的 SEC 文件，GatePass Capital LLC 持有 Oncology Institute 0.37% 的股份。</p>
</div><p>Get <strong>Oncology Institute</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Oncology Institute</strong> 的提醒：</p>
</div><p>Several other hedge funds have also modified their holdings of TOI. Goldman Sachs Group Inc. purchased a new position in Oncology Institute in the first quarter valued at $131,000. Geode Capital Management LLC boosted its holdings in Oncology Institute by 231.7% in the second quarter. Geode Capital Management LLC now owns 1,279,443 shares of the company's stock valued at $2,623,000 after purchasing an additional 893,696 shares during the period. Cetera Investment Advisers boosted its holdings in Oncology Institute by 35.0% in the second quarter. Cetera Investment Advisers now owns 17,545 shares of the company's stock valued at $36,000 after purchasing an additional 4,545 shares during the period. JPMorgan Chase &amp; Co. boosted its holdings in Oncology Institute by 51,631.5% in the second quarter. JPMorgan Chase &amp; Co. now owns 27,935 shares of the company's stock valued at $57,000 after purchasing an additional 27,881 shares during the period. Finally, New York State Common Retirement Fund purchased a new position in Oncology Institute in the second quarter valued at $92,000. 36.86% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他幾家對沖基金也調整了對 TOI 的持股。高盛集團在第一季度購買了價值 131,000 美元的 Oncology Institute 新頭寸。Geode Capital Management LLC 在第二季度將其在 Oncology Institute 的持股增加了 231.7%。Geode Capital Management LLC 目前持有 1,279,443 股該公司的股票，價值 2,623,000 美元，此前在此期間又購買了 893,696 股。Cetera Investment Advisers 在第二季度將其在 Oncology Institute 的持股增加了 35.0%。Cetera Investment Advisers 目前持有 17,545 股該公司的股票，價值 36,000 美元，此前在此期間又購買了 4,545 股。摩根大通在第二季度將其在 Oncology Institute 的持股增加了 51,631.5%。摩根大通目前持有 27,935 股該公司的股票，價值 57,000 美元，此前在此期間又購買了 27,881 股。最後，紐約州共同退休基金在第二季度購買了價值 92,000 美元的 Oncology Institute 新頭寸。目前，36.86% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>A number of research analysts recently issued reports on TOI shares. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Oncology Institute in a report on Monday, April 20th. B. Riley Financial lifted their target price on Oncology Institute from $6.00 to $8.00 and gave the company a &#34;buy&#34; rating in a report on Friday, March 13th. Needham &amp; Company LLC reiterated a &#34;buy&#34; rating and issued a $5.00 target price on shares of Oncology Institute in a report on Monday, March 9th. Finally, BTIG Research reiterated a &#34;buy&#34; rating and issued a $7.00 target price on shares of Oncology Institute in a report on Monday, March 9th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $7.00.</p>
<div class="lb-trans"><p>最近，一些研究分析師對 TOI 股票發佈了報告。Weiss Ratings 在 4 月 20 日的報告中重申了對 Oncology Institute 股票的 &#34;賣出 (d-)&#34; 評級。B. Riley Financial 在 3 月 13 日的報告中將 Oncology Institute 的目標價格從 6.00 美元上調至 8.00 美元，並給予該公司 &#34;買入&#34; 評級。Needham &amp; Company LLC 在 3 月 9 日的報告中重申了 &#34;買入&#34; 評級，並對 Oncology Institute 股票設定了 5.00 美元的目標價格。最後，BTIG Research 在 3 月 9 日的報告中重申了 &#34;買入&#34; 評級，並對 Oncology Institute 股票設定了 7.00 美元的目標價格。四位股票研究分析師對該股票給予了買入評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票目前的共識評級為 &#34;適度買入&#34;，共識目標價格為 7.00 美元。</p>
</div><p><strong>Read Our Latest Research Report on TOI</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 TOI 的最新研究報告</strong></p>
</div><h2>Insider Transactions at Oncology Institute</h2>
<div class="lb-trans"><h2>Oncology Institute 的內部交易</h2>
</div><p>In other news, Director Mohit Kaushal sold 38,433 shares of Oncology Institute stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $3.50, for a total transaction of $134,515.50. Following the sale, the director owned 172,583 shares in the company, valued at approximately $604,040.50. The trade was a 18.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett bought 33,500 shares of the business's stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $4.07 per share, for a total transaction of $136,345.00. Following the transaction, the insider directly owned 10,567,858 shares of the company's stock, valued at approximately $43,011,182.06. This represents a 0.32% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought 637,485 shares of company stock worth $2,038,896 in the last quarter. Insiders own 8.50% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，董事 Mohit Kaushal 於 4 月 16 日出售了 38,433 股 Oncology Institute 股票。該股票的平均售價為 3.50 美元，總交易額為 134,515.50 美元。出售後，該董事在公司中持有 172,583 股，價值約為 604,040.50 美元。此次交易使其持股減少了 18.21%。該交易已在向證券交易委員會提交的文件中披露，文件可通過此鏈接訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。此外，主要股東 Jorey Chernett 於 5 月 20 日購買了 33,500 股該公司的股票。該股票的平均購買價格為每股 4.07 美元，總交易額為 136,345.00 美元。交易後，內部人士直接持有 10,567,858 股該公司的股票，價值約為 43,011,182.06 美元。這代表其持股增加了 0.32%。該購買的披露信息可在 SEC 文件中找到。內部人士在上個季度購買了價值 2,038,896 美元的 637,485 股公司股票。內部人士持有該公司 8.50% 的股份。</p>
</div><h2>Oncology Institute Stock Performance</h2>
<div class="lb-trans"><h2>Oncology Institute 股票表現</h2>
</div><p>TOI opened at $4.59 on Tuesday. The business's 50-day simple moving average is $3.54 and its 200-day simple moving average is $3.33. The Oncology Institute, Inc. has a one year low of $2.02 and a one year high of $4.88. The stock has a market capitalization of $453.68 million, a P/E ratio of -12.41 and a beta of 0.33.</p>
<div class="lb-trans"><p>TOI 週二開盤價為 4.59 美元。該公司的 50 天簡單移動平均線為 3.54 美元，200 天簡單移動平均線為 3.33 美元。The Oncology Institute, Inc. 的一年低點為 2.02 美元，一年高點為 4.88 美元。該股票的市值為 4.5368 億美元，市盈率為 -12.41，貝塔值為 0.33。</p>
</div><p>Oncology Institute (NASDAQ:TOI - Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.05. The firm had revenue of $147.44 million for the quarter, compared to analyst estimates of $142.10 million. On average, equities research analysts forecast that The Oncology Institute, Inc. will post -0.2 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Oncology Institute (NASDAQ:TOI - 獲取免費報告) 最近一次發佈財報是在 5 月 7 日。該公司報告季度每股收益為 ($0.02)，超出分析師共識預期的 ($0.07) 0.05 美元。該公司季度收入為 1.4744 億美元，而分析師預期為 1.4210 億美元。平均而言，股票研究分析師預測 The Oncology Institute, Inc. 本財年將發佈 -0.2 的每股收益。</p>
</div><h2>Oncology Institute Profile</h2>
<div class="lb-trans"><h2>Oncology Institute 簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials &amp; Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.</p>
<div class="lb-trans"><p>The Oncology Institute, Inc. 是一家腫瘤學公司，在美國提供各種醫療腫瘤學服務。該公司通過三個部門運營：藥房、患者服務和臨牀試驗及其他。它提供醫生服務、內部輸液和藥房、臨牀試驗、放射治療、門診血液產品輸血和患者支持服務，以及教育研討會、支持小組和諮詢服務。該公司還提供管理臨牀試驗、姑息治療項目、幹細胞移植服務以及與非社區基礎的學術和三級護理設置相關的其他護理交付模式；併為一系列製藥和醫療設備公司進行臨牀試驗。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Oncology Institute</li>
<li>SpaceX Gets the Attention, But These 4 Stocks Could Get the Returns</li>
<li>Microsoft Stock Discount May Be Ending as AI Catalysts Build</li>
<li>Apparel Earnings Winners and Losers: Ralph Lauren Takes Off</li>
<li>Why Walmart, Target and TJX Got Such Different Reactions After Earnings</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Oncology Institute</li>
<li>SpaceX 引起關注，但這四隻股票可能帶來回報</li>
<li>微軟股票折扣可能結束，因 AI 催化劑增加</li>
<li>服裝收益贏家和輸家：拉爾夫·勞倫起飛</li>
<li>為什麼沃爾瑪、塔吉特和 TJX 在財報後反應如此不同</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TOI?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Oncology Institute, Inc. (NASDAQ:TOI - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有 TOI 的情況嗎？</strong> 訪問 HoldingsChannel.com 獲取 The Oncology Institute, Inc. (NASDAQ:TOI - 免費報告) 的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE9J" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TOI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒是由敍事科學技術和來自 MarketBeat 的金融數據生成的，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Oncology Institute Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Oncology Institute 嗎？</h2>
</div><p>Before you consider Oncology Institute, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Oncology Institute 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncology Institute wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Oncology Institute 並不在名單上。</p>
</div><p>While Oncology Institute currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Oncology Institute 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

GatePass Capital LLC Invests $1.28 Million in The Oncology Institute, Inc. $TOI

Market Beat

Oncology Institute

標普生物技術 3 倍做多 - Direxion

醫療業 ETF - Vanguard

標普生物技術 ETF - SPDR

醫療業 ETF - SPDR

動態生物技術與基因組 ETF - Invesco

標普醫療保健服務 ETF - SPDR

生物科技 ETF - VanEck Vectors

紐交所高增長板生物技術指數 ETF - First Trust

標普全球醫療股指數 ETF - iShares

美國醫療保健供應商 ETF - iShares

納斯達克生物科技指數 ETF - iShares Nasdaq

高盛

摩根大通

Oncology Institute - CW22

GS Hldg R

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B. Riley Financial-存託優先股A

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

GatePass Capital LLC 向 The Oncology Institute, Inc. $TOI 投資了 128 萬美元